Discover 436 paid clinical trials in Edmonton, . Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Edmonton has a research history that most cities cannot match: the first successful islet cell transplant protocol for type 1 diabetes, known worldwide as the Edmonton Protocol, was developed at the University of Alberta in 2000 and changed transplant medicine. Diabetes studies are still a local strength, alongside cancer research at the Cross Cancer Institute, the comprehensive cancer centre for northern Alberta since 1968. Of the roughly 500 studies recruiting in the city, about a third are in oncology, with multiple myeloma and breast cancer among the most common, and the rest span inflammatory bowel disease, pulmonary hypertension, and sleep apnea.
Filter
2
Filter results
Results: 436
Cycling-Based Aerobic Exercise Intervention for Individuals With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
for
Cancer, Adults
Location: Edmonton
Sponsor: University of Alberta
Sex: All
Age: 18+
Code: NCT07150117
Recruiting
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
for
Non-small Cell Lung Cancer
Location: Edmonton, Fruitland ID, Boise ID, Meridian ID, Nampa ID,
Sponsor: Canadian Cancer Trials Group
Sex: All
Age: 18+
Code: NCT06686771
Phase 3, Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
for
Cervical Cancer
Location: Edmonton, Calgary, Eugene OR, Edina MN, Omaha NE,
Sponsor: Merck Sharp & Dohme LLC
Sex: Female
Age: 18+
Code: NCT07216703
Phase 3, Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
for
Hepatocellular Carcinoma
Location: Edmonton, Seattle WA, Rochester MN, Palo Alto CA,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06921785
Phase 3, Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Edmonton, Calgary, Vancouver, Seattle WA, Vancouver WA,
Sponsor: BeOne Medicines
Sex: All
Age: 18+
Code: NCT06943872
Phase 3, Recruiting
Implementing REmote SymPtom mOnitoring and maNagement (RESPONd)
for
Cancer
Location: Edmonton, Red Deer, Calgary
Sponsor: University of Calgary
Sex: All
Age: 18+
Code: NCT07024329
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
for
Non-small Cell Lung Cancer
Location: Edmonton, Portland OR, Ogden UT, Reno NV, Roseville CA,
Sponsor: Boehringer Ingelheim
Sex: All
Age: 18+
Code: NCT07195695
Phase 3, Recruiting
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
for
Metastatic Head-and-neck Squamous-cell Carcinoma,
Location: Edmonton, Calgary, Westwood KS, Los Angeles CA,
Sponsor: AVEO Pharmaceuticals, Inc.
Sex: All
Age: 18+
Code: NCT06064877
Phase 3, Recruiting
Tamoxifen Versus Etoposide After First Recurrence in GBM Patients
for
Glioblastoma Multiforme
Location: Edmonton
Sponsor: AHS Cancer Control Alberta
Sex: All
Age: 18 - 65
Code: NCT04765098
Phase 2, Recruiting
Observational Study Protocol: LIVER-R
for
Hepatobiliary Cancers
Location: Edmonton, Calgary, Spokane WA, Walnut Creek CA,
Sponsor: AstraZeneca
Sex: All
Age: 18 - 70+
Code: NCT06252753
Recruiting
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
for
Relapsed/Refractory Multiple Myeloma
Location: Edmonton, Vancouver, Seattle WA, Salt Lake City UT,
Sponsor: BeOne Medicines
Sex: All
Age: 18+
Code: NCT04973605
Phase 1, Phase 2, Recruiting
Feasibility of Prospective Surveillance and Early Physical Therapy for Trismus